Promising Phase II subcutaneous Cinryze data in HAE to inform further trial design
This article was originally published in Scrip
Executive Summary
ViroPharma and Halozyme Therapeutics have announced positive top-line data from a Phase II trial of subcutaneous Cinryze (C1 esterase inhibitor [human]) in combination with recombinant human hyaluronidase enzyme (rHuPH20) in patients with hereditary angioedema (HAE).